Andere Sprachen Cyclo Therapeutics, Inc.

Aktien

A2QJRY

US23254X2018

CYTH

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 24.05.2024			% 5 Tage	% 1. Jan.
1,35 ^USD	+3,85 %		-3,57 %	-15,09 %

24.05.	Cyclo Therapeutics reicht $100 Millionen Mixed Shelf ein	MT
01.05.	CYCLO THERAPEUTICS, INC. : HC Wainwright bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Cyclo Therapeutics Files $100 Million Mixed Shelf	24.05.
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	16.05.
Cyclo Therapeutics : Corporate Presentation	02.05.
Cyclo Therapeutics : Corporate Presentation	18.04.
Cyclo Therapeutics : Corporate Presentation	18.03.
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	18.03.
Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18.03.
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol Cyclo for the Treatment of Alzheimer's Disease	15.03.
Cyclo Therapeutics Granted Patent Covering Use of Trappsol Cyclo for Alzheimer's Disease	14.03.
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease	14.03.
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office	30.01.
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office	29.01.
Cyclo Therapeutics : Modification to Rights of Security Holders - Form 8-K	28.12.
Cyclo Therapeutics, Applied Molecular Transport Complete Merger	27.12.
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.	27.12.
Cyclo Therapeutics, Inc. Appoints Shawn Cross to the Board of Directors	27.12.
Cyclo Therapeutics, Inc. completed the acquisition of Applied Molecular Transport Inc. from a group of shareholders for $10.2 million.	27.12.
Cyclo Therapeutics : Scientific Presentation	20.12.
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1	18.12.
Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1	18.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cyclo Therapeutics, Inc.

Aktien

A2QJRY

US23254X2018

CYTH

Andere Sprachen

Filter